Business Context and Reporting Period
Company: Nephros, Inc. (NEPH)
Filing Type: Form 8-K (Current Report)
Date of Report: May 17, 2022
Reporting Period: Single event date (May 17, 2022)
Nephros, Inc., a Delaware corporation, operates in the medical device sector. The filing reports a specific regulatory milestone achieved by the Company and its majority-owned subsidiary, Specialty Renal Products, Inc.
Key Financial Metrics
This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements, revenue figures, profit data, cash flow information, margin analysis, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
The material change reported is a regulatory approval rather than a financial variance:
- Regulatory Clearance: On May 17, 2022, the Company received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
- Product: The clearance applies to the Company's patented, second-generation HDF Assist Module.
- Developer: The module was developed by Specialty Renal Products, Inc., the Company's majority-owned subsidiary.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release (Exhibit 99.1) announcing the FDA clearance. No specific financial guidance, future revenue outlook, or management commentary regarding financial performance is included in this document.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard regulatory context of seeking and obtaining FDA clearance. No unusual items are reported.
Investor Verification Checklist
- Verify the commercial launch timeline and market availability of the second-generation HDF Assist Module following FDA clearance.
- Review the full text of the press release (Exhibit 99.1) for details on the competitive advantages of the new module.
- Confirm the ownership structure and operational status of the subsidiary, Specialty Renal Products, Inc.
- Check subsequent filings (e.g., 10-Q or 10-K) for the financial impact of this product launch on revenue and operating expenses.